Business
Colgate-Palmolive markets oral-care, personal-care, home-care and pet-nutrition products worldwide.
Colgate-Palmolive: Revenue grew 1.4% to $20.382B from $20.101B. Net income declined 26.2% to $2.132B from $2.889B. Free cash flow grew 2.5% to $3.634B from $3.546B. Operating margin contracted 501 bps to 16.22%. Colgate-Palmolive's annual comparison also shows stock compensation grew faster than revenue.
The read at a glance✓ Audited against SEC data
- Growth — Revenue grew 1.4%OK
- Profitability — Net income declined 26.2% to $2.132B from $2.889BWatch
- Cash flow — Free cash flow grew 2.5% to $3.634B from $3.546BOK
- Margins — Operating margin contracted 501 bps to 16.22%Watch
- Accounting — No overriding statistical warningNote
- Insiders — 0 purchases and 11 salesWatch
Where the revenue comes from
Fiscal 2025, as COLGATE PALMOLIVE CO reports it. History and quarterly detail are in the app.
- Total Oral, Personal and Home Care$15.8B
- Pet Nutrition$4.6B
Leadership changes
From COLGATE PALMOLIVE CO's own filings, the day they're filed.
- Michael B. Polk · Directors · departureeff. 2023-08-18
Latest filings
- 8-K · Company announcement2026-07-31
- 10-Q · Quarterly report2026-07-31
- 8-K · Company announcement2026-05-13
- 8-K · Company announcement2026-05-01
- 10-Q · Quarterly report2026-05-01
In the full recordFree for 14 days
- What changed🔒
- Insider signal🔒
- Growth quality🔒
- Margins & accounting🔒
- Capital allocation🔒
- Real risks🔒
- The long arc🔒
- Company history🔒
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about COLGATE PALMOLIVE CO, every answer cited to the official filings🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.